Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.56M | 1.51M | 1.89M | 1.48M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.38M | 4.06M | 4.67M | 2.65M | 3.43M |
| Operating Income | -3.38M | -4.06M | -4.67M | -2.65M | -3.43M |
| Income Before Tax | -3.10M | -3.73M | -4.31M | -2.39M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.10M | -3.73M | -4.31M | -2.39M | -3.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -230.70K | -81.80K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -3.73M | -4.31M | -2.62M | -3.18M |
| EBIT | -3.38M | -4.06M | -4.67M | -2.65M | -3.43M |
| EBITDA | -- | -- | -- | -2.63M | -3.42M |
| EPS Basic | -0.06 | -0.07 | -0.08 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.05 | -0.03 | -0.04 |
| EPS Diluted | -0.06 | -0.07 | -0.08 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.05 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 52.65M | 52.64M | 52.63M | 52.58M | 52.32M |
| Average Diluted Shares Outstanding | 52.65M | 52.64M | 52.63M | 52.58M | 52.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
